← Back to patent-cliff list
多替拉韦/拉米夫定/艾酚福韦
Tier C — Watch / tradeDolutegravir/Lamivudine/Tenofovir Alafenamide
Cipla Usa Inc
Originator
2019
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：HIV integrase、RT
Indications (approved)：HIV感染
Regional status
US
批准上市
2019-09-11
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Dolutegravir/Lamivudine/Tenofovir Alafenamide?
Approved indications include: HIV感染.
When does the Dolutegravir/Lamivudine/Tenofovir Alafenamide patent expire?
No public expiry year is available for Dolutegravir/Lamivudine/Tenofovir Alafenamide yet; this page updates once verified.
How do I get a quote for Dolutegravir/Lamivudine/Tenofovir Alafenamide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24